Financial Contrast: Elicio Therapeutics (ELTX) and Its Competitors

Elicio Therapeutics (NASDAQ:ELTX) is one of 607 public companies in the “MED – BIOMED/GENE” industry, but how does it contrast to its competitors? We will compare Elicio Therapeutics to similar companies based on the strength of its profitability, dividends, earnings, institutional ownership, risk, analyst recommendations and valuation.

Profitability

This table compares Elicio Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-2,748.16%	-151.12%
Elicio Therapeutics Competitors	-846.28%	-107.82%	-27.64%

Risk and Volatility

Elicio Therapeutics has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Elicio Therapeutics’ competitors have a beta of 1.05, meaning that their average share price is 5% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Elicio Therapeutics and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1	1	4	0	2.50
Elicio Therapeutics Competitors	8816	13398	40769	1416	2.54

Elicio Therapeutics presently has a consensus target price of $19.75, indicating a potential upside of 513.35%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 51.36%. Given Elicio Therapeutics’ higher probable upside, equities analysts clearly believe Elicio Therapeutics is more favorable than its competitors.

Insider & Institutional Ownership

35.0% of Elicio Therapeutics shares are owned by institutional investors. Comparatively, 51.2% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 50.9% of Elicio Therapeutics shares are owned by insiders. Comparatively, 12.1% of shares of all “MED – BIOMED/GENE” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Elicio Therapeutics and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Elicio Therapeutics	N/A	-$39.57 million	-1.34
Elicio Therapeutics Competitors	$917.38 million	$68.12 million	-30.50

Elicio Therapeutics’ competitors have higher revenue and earnings than Elicio Therapeutics. Elicio Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Elicio Therapeutics competitors beat Elicio Therapeutics on 7 of the 13 factors compared.

About Elicio Therapeutics

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.